MARKET

NLNK

NLNK

NewLink Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.600
+0.030
+1.91%
After Hours: 1.600 0 0.00% 16:00 02/21 EST
OPEN
1.570
PREV CLOSE
1.570
HIGH
1.710
LOW
1.550
VOLUME
528.37K
TURNOVER
--
52 WEEK HIGH
3.600
52 WEEK LOW
1.130
MARKET CAP
59.73M
P/E (TTM)
-1.3170
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NLNK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NLNK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

NLNK News

More
  • NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
  • Zacks · 5d ago
  • Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries
  • MarketWatch · 02/01 15:53
  • Benzinga's Top Upgrades, Downgrades For January 3, 2020
  • Benzinga · 01/03 16:33
  • RAD, NIO, FCEL and NLNK among midday movers
  • Seeking Alpha - Article · 12/30/2019 17:41

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About NLNK

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
More

Webull offers kinds of NewLink Genetics Corp stock information, including NASDAQ:NLNK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLNK stock news, and many more online research tools to help you make informed decisions.